If You're Not Using AI in Validation Yet, You're Already Behind - Bruce Klopfenstein

95% of our viewers aren't subscribed. If you're watching and not yet subscribed, please subscribe to the channel so you don't miss future episodes. What does it actually take to deliver a pharmaceutical facility project without it going off the rails? This week, Thomas McMann sat down with someone who has spent over 30 years doing exactly that, from both sides of the table. This week on Making It In Manufacturing, Thomas McMann sat down with Bruce Klopfenstein, Project Manager at @GSK, with over 30 years of experience spanning project management, engineering, validation, EPC consulting, and client-side leadership across companies including @GSK, @Jacobs, @JohnsonAndJohnson, @Fujifilm and @IBM. In this episode, Bruce covers: Why getting ACV engaged at the very start of a project changes everything, and why the industry has been slow to do it. Who is actually responsible when a pharmaceutical project goes over budget, and why change control is almost always at the root of it. The $100,000 mistake that came down to a missing piece of paper, and the engineer who had to fly to Europe during Covid to fix it. How @GSK is leading a major sustainability push through its low-carbon inhaler propellant project in France, and why 49% of their total annual emissions trace back to a single product type. Why AI adoption in pharmaceutical validation is no longer optional, and how companies like @GSK and @Eli Lilly are already using it inside the firewall, with Bruce's take on @ValKit AI and what large language models can do for protocol generation at scale. This is a genuinely experienced perspective on what it takes to manage complex pharmaceutical projects, and what the industry needs to do differently. Worth your time whether you are on the EPC side, the client side, or deep in the validation world. Follow ARTO LinkedIn:   / artotalent   Spotify: https://open.spotify.com/show/0kEcRZO... Instagram: https://www.instagram.com/arto.talent... TikTok: https://www.tiktok.com/@artotalent?_t... Apple Podcasts: https://podcasts.apple.com/us/podcast... Website: https://arto-talent.com/ Youtube:    / @artotalent   LinkedIn Bruce Klopfenstein LinkedIn:   / bruceklopfenstein   Thomas McMann LinkedIn:   / thomas-mcmann-05540a10b   Timestamps: 0:00 Introduction 1:40 Bruce's ISP talk: early ACV engagement from Basis of Design through Detailed Design 3:13 Bruce's career journey: IBM, PricewaterhouseCoopers, gaming industry, J&J, and life science 6:00 Skills carried across industries: data architecture, management consulting, and project management 8:09 Finding the most enjoyable moments: it is about the team and the situation, not just the job 10:49 Current role: Project Manager at GSK on the low-carbon inhaler propellant project in France 13:13 Engineering complexity of the 152A propellant transition and where the project currently stands 14:25 Was Bruce brought in early enough? What that has meant for phase two 16:33 The CO2 comparison between pharma and automotive: why the headline is misleading 19:10 The public perception problem facing the pharmaceutical industry 19:54 Who is responsible when a project goes over budget? EPC vs client-side accountability 22:02 Change control as the primary driver of delays 23:08 The biggest differences between working on the EPC side vs the client side 24:34 Where misalignment typically occurs between client and EPC 25:20 Why relationships are the foundation of every successful project 27:13 The most expensive small oversight: a $100k lesson in missing material certifications 30:10 EPC stress vs owner stress: where the real pressure sits 33:38 The worst project delay Bruce has experienced and what caused it 36:18 Why pharma struggles to standardise the way oil and gas has 37:54 Why projects get delayed: starting before you are ready 40:04 Change control in practice: what it actually requires 42:10 How long should IQ, OQ, and PQ phases realistically take? 43:07 Equipment lead times and Covid-era supply chain pressure on the critical path 44:11 Fujifilm and the standardisation debate: new technology versus proven design 45:44 AI in pharmaceutical validation: where the industry is today 46:26 ValKit AI and Hugh Devine: using LLMs to generate validation protocols 47:18 The FDA's first AI warning letter and what it means for human oversight 48:53 Real examples of AI making a difference: SOPs, protocols, and training in minutes 53:31 How to think about AI like a smart intern: natural language, not programming 55:38 Why companies that are not adopting AI now will fall behind 56:00 Closing thoughts and sign-off #MakingItInManufacturing #ARTOTalent #ProjectManagement #Validation #LifeSciences #Biotech #AIInPharma #Commissioning #GMP #DrugManufacturing #Sustainability #GSK #EPC